Skip to Content

'
John C. Araujo, MD, PhD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler Street
Unit 1374
Houston, TX 77030
Room Number: CPB7.3466
Phone: 713-563-7203
Fax: 713-745-1625

Education & Training

Degree-Granting Education

2000 Stritch School of Medicine Loyola University Chicago, Maywood, IL, MD, Medicine
1996 Georgetown University School of Medicine, Washington, DC, PHD, Microbiology and Immunology
1991 Fairfield University, Fairfield, CT, BS, Biology

Postgraduate Training

7/2003-6/2006 Clinical Fellowship, Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
7/2001-6/2003 Clinical Residency, Internal Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH
7/2000-6/2001 Clinical Internship, Internal Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH

Board Certifications

10/2006 American Board of Internal Medicine-Medical Oncology
8/2003 American Board of Internal Medicine-Internal Medicine

Experience/Service

Academic Appointments

Instructor, Emergency Department, Darmouth Hitchcock Medical Center, Lebanon, NH, 10/2002-6/2003

Other Appointments/Responsibilities

Reviewer for Medical Oncology, American Board of Internal Medicine, Houston, TX, 11/2007-present

Institutional Committee Activities

Committee Member, Council of Committee Chairs, 3/2008-present
Vice Chairman, Pharmacy and Therapeutics Committee, 2/2008-8/2008
Committee Member, Department Protocol Review, 11/2007-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Varkaris A, Katsiampoura AD, Araujo JC, Gallick GE, Corn PG. Src signaling pathways in prostate cancer. Cancer Metastasis Rev. e-Pub 2/2014. PMID: 24522479.
2. Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. e-Pub 1/2014. PMID: 24473064.
3. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol 14(13):1307-16, 12/2013. e-Pub 11/8/2013. PMID: 24211163.
4. Richey SL, Tamboli P, Ng CS, Lin E, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM. Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Locally Advanced and Metastatic Nonclear Cell Renal Cell Carcinoma. Am J Clin Oncol 36(5):450-4, 10/2013. e-Pub 6/2012. PMID: 22706175.
5. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. Clin Cancer Res 19(13):3621-30, 7/2013. e-Pub 5/2013. PMCID: PMC3699964.
6. Ng L, Heck W, Lavsa S, Crowther D, Atkinson B, Xiao L, Araujo J. The Lack of Predictors for Rapid Progression in Prostate Cancer Patients Receiving Sipuleucel-T. Cancers 5(2):511-18, 5/2013.
7. Eser PO, Vanden Heuvel JP, Araujo J, Thompson JT. Marine-and plant-derived w-3 fatty acids differentially regulate prostate cancer cell proliferation. Molecular and Clin Oncol 76(1):444-452, 2/2013. PMCID: PMCPMC3916163.
8. Araujo JC, Trudel GC, Paliwal P. Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel. Cancer Manag Res 6(6):25-30, 2013. e-Pub 3/2013. PMCID: PMC3601649.
9. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma. Eur Urology 62(6):1013-9, 12/2012. PMID: 22771265.
10. Ameri H, Araujo JC, Gombos DS. Leuprolide monotherapy for choroidal metastasis from prostate adenocarcinoma. Arch Ophthalmol 130(9):1225-6, 9/2012. PMID: 22965610.
11. Araujo, JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1-2 study. Cancer 118(1):63-71, 1/2012. NIHMSID: NIHMS494060.
12. Roychowdhury S, Lyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 111:111ra121, 11/2011. PMID: 22133722.
13. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 71(8):846-56, 6/2011. PMCID: PMCPMC3883511.
14. Lee YC, Huang CF, Murshed M, Chu K, Araujo JC, Ye X, deCrombrugghe B, Yu-lee LY, Galick GE, Lin SH. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene 29(22):3196-207, 6/2010. PMID: 20228840.
15. Araujo J, Logothetis C. Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev, 3/2010. PMID: 20226597.
16. Araujo JC, Poblenz A, Parikh NU, Starbuck MW, Thompson JT, Lee F, Logothetis CJ, Darnay BG. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation. Cancer Biol & Therapy 8(22):2153-59, 11/2009. PMID: 19855158.
17. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-81, 9/2009. PMID: 19636008.
18. Araujo J, Logothetis C. Targeting Src signaling in metastatic bone disease. Int J Cancer 124(1):1-6, 1/2009. PMID: 18942061.
19. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim SJ, Wang Z, Gallick GE. Targeting Src family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 68(9):3323-33, 3/2008. PMID: 18451159.

Abstracts

1. Araujo JC, Trudel GC, Saad F, Armstrong AJ, YU EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Malveev V, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, DeBono JS, Paliwal P, Durham S, cheng S, Logothetis C. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. J Clin Oncol (#LBA8), 2/2013.
2. Dayyani F, Gallick GE, Thompson JT, Trudel GC, Logothetis C, Araujo JC. Correlation of dasatinib (DAS) peak levels with interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) levels in patients with castration-resistant progressive prostate cancer (CRPC). J Clin Oncol 28(15S):382s (#4665), 6/2010.
3. Dayyani F, Gallick GE, Trudel GC, Logothetis C, Araujo JC. Decline in bone markers and response to combination therapy with dasatinib and docetaxel in patients with castration-resistant progressive prostate cancer (CRPC). Genitourinary Cancers Symposium Proceedings (#136), 2/2010.
4. Araujo J, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. Dasatinib and docetaxel combination treatment for patients with castration-resistance progressive prostate cancer: A phase I/II study (CA180086). J Clin Oncol 27(15S):249s (#5061), 2/2009.
5. Araujo J, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick G, Trudel GC, Paliwal P, Logothetis CJ. Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer: analysis of Study CA180-086. Eur J Cancer Suppl 7:415S (#7028), 2009.
6. Araujo JC, Jonasch E, Tannir N, Bekele BN, Lin E, Plimack ER. Patterns of progression in renal cell carcinoma: antivascular therapy compared with interferon. J Clin Oncol 26(15S):276s (#5106), 5/2008.
7. Jonasch E, Woods, CG, Matin S, Tamboli P, Do K, Pagliaro C, Aparicio A, Araujo J, Tannir NM. Presurgical bevacizumab in patients with metastatic lear cell renal cell carcinoma: A phase II study. J Clin Oncol 26(15S):275s (#5104), 5/2008.
8. Zurita AJ, Ward JF, Araujo JC, Pettaway Ca, Pisters LL, Dieringer P, Troncoso P, Logothetis CJ. Presurgical sunitinib malate and androgen ablation in patients with localized prostate cancer at high risk for recurrence. J Clin Oncol 26(15S):271s (#16004), 5/2008.
9. ER Plimack, E Jonasch, BN Bekele, LA Smith, JC Araujo, NM Tannir. Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC): A phase II study. J Clin Oncol 26(15S):277s (#5112), 5/2008.
10. Aparicio AM, Lin AM, Araujo JC, Logothetis JC, Kim J, Pagliaro LC, Tu S, Guo C, Jones D, Thall P, Mathew P. Use of clinical features to select a chemotherapy-responsive variant of aggressive prostate cancer. J Clin Oncol 26(15S):271s (#16000), 5/2008.

Grant & Contract Support

Title: M. D. Anderson Cancer Center Prostate SPORE
Funding Source: NIH/NCI
Role: Co-Program Leader
Principal Investigator: Christopher Logothetis
Duration: 9/2/2009 - 8/31/2014
 
Title: Role of Fibroblast Growth Factor 9 in Prostate Cancer Bone Metastasis
Funding Source: U T M. D. Anderson Cancer Center
Role: Principal Investigator-MDACC
Duration: 10/1/2006 - 10/1/2007
 
Funding Source: U T M. D. Anderson Cancer Center
Role: Postdoctoral Fellow
Principal Investigator: Waun Ki Hong, MD
Duration: 1/1/2005 - 6/30/2006

Last updated: 12/17/2014